Cortexyme Stock Sinks After FDA Puts Application on Hold

Options volume is running at triple the intraday average

Digital Content Manager
Jan 26, 2022 at 3:21 PM
facebook twitter linkedin


Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold. This development follows a late-to-mid-stage study, which revealed COR388 failed to improve overall cognitive function in patients. In turn, the company is looking to implement a cost reduction program, and will prioritize the development of a different treatment for the illness.

The equity earlier fell to a record low of $5.60, a far cry from its Aug. 10 all-time high of $121.98. Overhead pressure from the 40-day moving average has kept a tight lid on CRTX over the past few months, with the shares now pacing for their fifth-straight loss. Longer term, the security carries a massive 83.3% year-over-year deficit.

CRTX 40 Day

Short sellers are firmly in control. Short interest rose 5.3% in the most recent reporting period, and the 8.87 million shares sold short make up 44.5% of CRTX's available float, which is equivalent to almost four days' worth of pent-up buying power.

Headwinds could keep blowing for Cortexyme stock, should there be a shift in the options pits. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 50-day call/put volume ratio of 4.99 sits higher than 96% of readings from the past year. This indicates long calls have been more popular than usual of late.

Drilling down to today's options activity, 5,495 calls and 3,014 puts have crossed the tape so far, which is triple the intraday average. The most popular contract by far is the January 2023 5-strike put, where positions are currently being opened, followed by the April 15 call.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners